Company / Accounts Receivable
Eton Pharmaceuticals, Inc. Accounts Receivable History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$11.8M
FY2025
5-year range
$1.9M / $11.8M
FY2021-FY2025
Trend
+119.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has increased for 3 consecutive years, from $2M in FY2022 to $12M in FY2025.
Based on SEC 10-K filings.
$12M in FY2025 with a 5-year CAGR of +200.5%.
Improved from $3M to $12M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +85.2%
- 5-Year CAGR
- +200.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- Eton Pharmaceuticals, Inc.'s accounts receivable has grown for 3 consecutive years.
- 5-year CAGR of +200.5%, indicating consistent growth.
- In FY2025, accounts receivable increased 119.3% year-over-year.
- Lowest accounts receivable in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.63 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $11.8M | +119.3% |
| FY2024 | $5.4M | +57.2% |
| FY2023 | $3.4M | +84.2% |
| FY2022 | $1.9M | -66.1% |
| FY2021 | $5.5M | +11297.9% |
| FY2020 | $48.0K | -89.9% |
| FY2019 | $473.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026